Posts tagged as:

pharmaceuticals

September 19 roundup

by Walter Olson on September 19, 2011

  • Educator: please don’t bring lawyers to parent-teacher meetings [Ron Clark, CNN] Steve Brill: what I found when I investigated NYC teacher “rubber rooms” [Reuters] “The Six Dumbest Things Schools Are Doing in the Name of Safety” [Cracked] School waterfall liability [Lincoln, Neb. Journal-Star]
  • As predicted: “Dodd-Frank Paperwork a Bonanza for Consultants and Lawyers” [NYT]
  • “Running out of common drugs” [Josh Bloom, NY Post] Pharmaceutical shortages: the role of Medicare price controls [Richard Epstein, Hoover; earlier here, here, etc.]
  • DoT insists on exposing private flight plans online. Yoo-hoo, privacy advocates? [Steve Chapman]
  • New class action law in Mexico includes loser-pays provision [WSJ]
  • Newt Gingrich candidacy revives memories of his 1995 call for death penalty (with “mass executions”) for drug smuggling [NYT archive via Josh Barro; see also @timothy_watson "Sounds kinda like Shariah Law to me.")
  • "Cy pres slush fund in Georgia under ethics investigation" [PoL]

{ 3 comments }

September 14 roundup

by Walter Olson on September 14, 2011

{ 3 comments }

September 7 roundup

by Walter Olson on September 7, 2011

  • Truth through intimidation? U.K.: “Chronic fatigue syndrome researchers face death threats from militants” [Guardian] Nanotechnologists are target of Unabomber copycat [Chronicle of Higher Education]
  • Blogger (and frequent Overlawyered commenter) Amy Alkon criticizes intrusive TSA agent by name, agent threatens $500K libel suit [Mike Masnick/TechDirt, Mark Bennett]
  • NYT fans “pill mill” hysteria, heedless of the costs [Sullum]
  • Patent litigant “pursued baseless infringement allegations in bad faith and for an improper purpose.” More loser-pays, please [NLJ, PoL]
  • Great moments in link solicitation [Scott Greenfield] Quality bar at feminist lawprof blog may not be set terribly high [Popehat]
  • “Wow, this photo got over 475 views from being reposted on Overlawyered” [Erik Magraken]
  • “Popular Comic Strip Has Fun With Wacky Warnings” [Bob Dorigo Jones]

{ 5 comments }

August 29 roundup

by Walter Olson on August 29, 2011

{ 1 comment }

Gasp-worthy

by Walter Olson on July 25, 2011

The Food and Drug Administration has banned the only over-the-counter asthma inhaler, Primatene Mist, on the grounds that it releases chlorofluorocarbons (CFCs) and is thus bad for the ozone layer. [Chris Horner, Big Government via Alkon; Washington Post](& welcome Above the Law readers)

More from @larkinrule: “I was alone at my family cabin had an asthma attack and no inhaler. The corner store had one left. I believe it saved my life.”

{ 6 comments }

The Supreme Court’s admirable Twombly and Iqbal precedents give a federal district court the means to turn back a shotgun lawsuit against a horde of undifferentiated defendants [McFarland v. APP Pharmaceuticals LLC, slip op., 2011 WL 2413797 (W.D. Wash. June 13, 2011) via Beck, Drug and Device Law]. Quoting the court:

[A]lleging that 93 defendants all manufactured, distributed, and/or sold all of the products that caused all of plaintiff’s injuries is not plausible. In addition, plaintiff’s allegations are internally inconsistent. The complaint alleges that “each” of the defendants manufactured the heparin that caused her injuries, but also alleges that each of the 93 defendants “separately manufactured, marketed, distributed, wholesaled, and/or sold” heparin. The inconsistencies between those allegations, which are not pled in the alternative, further highlight the implausibility of plaintiff’s allegations.

James Beck writes, “Basically, the plaintiffs in McFarland didn’t want to do even the most basic spadework of identifying the correct defendants before bringing suit, so they threw in the kitchen sink in the hope that the defendants would end up having to spend the time and effort to figure things out.” After Twombly and Iqbal, that’s become a less effective legal tactic — one of many reasons to resist the Litigation Lobby drive to get Congress to overturn the two pleading decisions.

{ 2 comments }

Bloomberg columnist Ramesh Ponnuru tackles the pharmaceutical-shortage issue covered recently in this space.

P.S. Although it is only indirectly related to the issue of manufacturing shortages, note also the interesting reader comment on the gout drug Colchicine, known and used for millennia. Per relatively recent FDA rules, colchinine and various other older drugs, formerly “grandfathered” and free for anyone to produce, have been awarded in exclusivity to a single manufacturer, at considerable cost to consumers.

{ 5 comments }

I’ve got a post at Cato at Liberty getting into more detail about some of the deadly side effects of Food and Drug Administration (FDA) regulation, an issue raised previously in this space.

{ 3 comments }

June 8 roundup

by Walter Olson on June 8, 2011

  • Law firm settles with employee who said required high heels led to back injury [ABA Journal]
  • Stock listings fleeing U.S. for overseas, legal environment a factor [Ribstein, TotM]
  • Partial solution to above? Ted Frank places a stock bet on the Wal-Mart case [PoL, more]
  • Wider press coverage of hospital drug shortage [AP, Reuters, my March post]
  • Trial judge up north supports certifying as class action unusual suit blaming Newfoundland for moose collisions [Canadian Press via Karlsgodt, earlier here and here]
  • Academic revolt against copyright overreach [Chron of Higher Ed]
  • Sues deceased grandmother over trampoline injury [Madison County Record]

{ 3 comments }


Could it be that Rep. Henry Waxman (D-Calif.) — known for his extensive involvement in pharmaceutical issues over many years as a Congressional nabob, and for his long, close alliance with the plaintiff’s bar — is really unfamiliar with the story of Bendectin, one of the staple horror stories of litigation run amok in the drug field? [Carter Wood, ShopFloor] Background here, here, here, etc., etc. The whole clip, starring Rep. Brian Bilbray (R-CA), is worth watching: Bilbray wonders aloud whether there are any lawyers he can sue when unfounded lawsuits put needed medical technologies out of reach.

The maker of Botox is hit with a $212 million jury award [Richmond Times-Dispatch]

April 27 roundup

by Walter Olson on April 27, 2011

{ 3 comments }

April 22 roundup

by Walter Olson on April 22, 2011

{ 1 comment }

I’ve got a new post up at Cato at Liberty on the avoidable medical crisis brought about in part by an FDA crackdown — and how the government might manage to make it still worse. I quote commenter “Greg S.” from our earlier thread (& White Coat).

{ 11 comments }

Recent toughening of FDA regulation, particularly over the drug manufacturing process, is said to be a factor. Should this count as surprising? [LATimes]

{ 8 comments }

Advice from a physician

by Walter Olson on February 28, 2011

Don’t stop taking your medication just because you saw a lawyer referral ad on TV that claimed it was dangerous [Throckmorton, related]

{ 3 comments }

Headline from last August, recalled by James Taranto: “Milwaukee teachers union files suit over lack of Viagra coverage.” The lack of coverage for erectile dysfunction drugs amounted to sex discrimination, according to the complaint. [Journal-Sentinel]

More on the Wisconsin union showdown from Cato Institute scholars Chris Edwards (Virginia has much sharper restrictions on public-employee unionism than what Gov. Scott Walker is proposing), Neal McCluskey (for the kids? really?), David Boaz (president, with his entire political machine, “is inserting himself into a medium-sized state’s battle over how to balance its budget,” Roger Pilon (unions’ quarrel is with voters) — and see also this 2009 background paper on the unsustainable costs of some union victories.

{ 1 comment }

The plaintiff, who had been prescribed Zoloft and Ambien, “reportedly fell asleep while ‘inspecting’ his gun” and shot himself inadvertently on waking. He “is now suing his doctor for medical malpractice, saying that prescribing both an anti-depressant and a sleep aid together deviated from accepted standards of medical care. He has a separate product liability claim pending against the drug manufacturers.” [New Jersey Lawsuit Reform Alliance, FindACase]

{ 12 comments }